Rossari Biotech Limited (Rossari), an innovative speciality-chemicals manufacturer providing intelligent, sustainable and made in India solutions for customers across industries, today announced the launch of Dr. Nanoxa a new age antimicrobial surface coating infused with nanotechnology which provides bio-security from residual infections caused by bacteria, viruses including SARS CoV for 30 days.

The product is made in India and has successfully been tested by National Accreditation Board for Testing and Calibration Laboratories (NABL) certified laboratories using international standards and has proven to inactivate UTI causing bacteria and SARS-CoV-2 (Coronavirus) for 30 days of application. Another distinguishing feature of the product is its environment friendly coating which takes away the negative effects of the chemicals. 

Commenting on the launch, Amrutraj Kulkarni, Vice-President, Buzil Rossari Pvt. Ltd (a subsidiary of Rossari Biotech Limited) said, ““Covid has changed the way people perceive hygiene at home and at workplaces. Health of family and employees have become top priority for people and they are looking for effective and affordable ways to ensure the same. We recognised that disinfecting every single day was becoming cost and labour intensive and Dr. Nanoxa resolves both the issues. This will be applicable across several industries like hospitality, commercials establishments, hospitals and medical facilities, public spaces like airports and courts among many other such places. We are hopeful that the product will be received well by our customers.”

Initially, the company will be launching with a 200ml spray bottle for the B2C segment and five-litre cans along with empty spray bottles for the B2B/institutional segment.

He further added, “We are also planning an annual subscription model for the consumer market in which a 200ml Dr. Nanoxa spray bottle, microfibre cloth and instructions for use will be delivered to the consumer’s doorstep once a month, with a price advantage for the whole year’s subscription. We are confident that this range will be very well received by individual and institutional customers.”